Podcast appearances and mentions of William D Tap

Go online to PeerView.com/UVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Understanding practical considerations with systemic therapy in tenosynovial giant cell tumor (TGCT) can be critical for safe delivery of therapy. In this activity, an expert medical oncologist provides a practical update on targeted treatment options for TGCT management, with a focus on safe delivery of care—including appropriate dosing, food effects, and safety considerations—based on the current clinical experience with approved CSF1R inhibitors. Upon completion of this CE activity, participants will be able to: Manage safety and dosing considerations with targeted agents in the setting of TGCT.

Go online to PeerView.com/UVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Understanding practical considerations with systemic therapy in tenosynovial giant cell tumor (TGCT) can be critical for safe delivery of therapy. In this activity, an expert medical oncologist provides a practical update on targeted treatment options for TGCT management, with a focus on safe delivery of care—including appropriate dosing, food effects, and safety considerations—based on the current clinical experience with approved CSF1R inhibitors. Upon completion of this CE activity, participants will be able to: Manage safety and dosing considerations with targeted agents in the setting of TGCT.

Go online to PeerView.com/UVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Understanding practical considerations with systemic therapy in tenosynovial giant cell tumor (TGCT) can be critical for safe delivery of therapy. In this activity, an expert medical oncologist provides a practical update on targeted treatment options for TGCT management, with a focus on safe delivery of care—including appropriate dosing, food effects, and safety considerations—based on the current clinical experience with approved CSF1R inhibitors. Upon completion of this CE activity, participants will be able to: Manage safety and dosing considerations with targeted agents in the setting of TGCT.

Go online to PeerView.com/UVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Understanding practical considerations with systemic therapy in tenosynovial giant cell tumor (TGCT) can be critical for safe delivery of therapy. In this activity, an expert medical oncologist provides a practical update on targeted treatment options for TGCT management, with a focus on safe delivery of care—including appropriate dosing, food effects, and safety considerations—based on the current clinical experience with approved CSF1R inhibitors. Upon completion of this CE activity, participants will be able to: Manage safety and dosing considerations with targeted agents in the setting of TGCT.

Go online to PeerView.com/UVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Understanding practical considerations with systemic therapy in tenosynovial giant cell tumor (TGCT) can be critical for safe delivery of therapy. In this activity, an expert medical oncologist provides a practical update on targeted treatment options for TGCT management, with a focus on safe delivery of care—including appropriate dosing, food effects, and safety considerations—based on the current clinical experience with approved CSF1R inhibitors. Upon completion of this CE activity, participants will be able to: Manage safety and dosing considerations with targeted agents in the setting of TGCT.

Go online to PeerView.com/UVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Understanding practical considerations with systemic therapy in tenosynovial giant cell tumor (TGCT) can be critical for safe delivery of therapy. In this activity, an expert medical oncologist provides a practical update on targeted treatment options for TGCT management, with a focus on safe delivery of care—including appropriate dosing, food effects, and safety considerations—based on the current clinical experience with approved CSF1R inhibitors. Upon completion of this CE activity, participants will be able to: Manage safety and dosing considerations with targeted agents in the setting of TGCT.

Go online to PeerView.com/UVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Understanding practical considerations with systemic therapy in tenosynovial giant cell tumor (TGCT) can be critical for safe delivery of therapy. In this activity, an expert medical oncologist provides a practical update on targeted treatment options for TGCT management, with a focus on safe delivery of care—including appropriate dosing, food effects, and safety considerations—based on the current clinical experience with approved CSF1R inhibitors. Upon completion of this CE activity, participants will be able to: Manage safety and dosing considerations with targeted agents in the setting of TGCT.

Go online to PeerView.com/UVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Understanding practical considerations with systemic therapy in tenosynovial giant cell tumor (TGCT) can be critical for safe delivery of therapy. In this activity, an expert medical oncologist provides a practical update on targeted treatment options for TGCT management, with a focus on safe delivery of care—including appropriate dosing, food effects, and safety considerations—based on the current clinical experience with approved CSF1R inhibitors. Upon completion of this CE activity, participants will be able to: Manage safety and dosing considerations with targeted agents in the setting of TGCT.

William D. Tap, MD, Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center, gives an overview of tenosynovial giant cell tumors (TGCT), their symptoms, and why a multidisciplinary team is needed to treat them.

Go online to PeerView.com/SUZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView virtual activity, following the 2020 connective tissue oncology annual meeting, a panel of leading clinicians provides insights on important medical evidence supporting targeted agents in tenosynovial giant cell tumor (TGCT), and modern, practical recommendations for overcoming patient care challenges in the management of TGCT. The panel will also provide a multidisciplinary perspective on real-world clinical scenarios and discuss how novel targeted therapeutics have enhanced a long-standing treatment landscape. Upon completion of this activity, participants should be better able to: Describe the clinical signs and symptoms of localized and diffuse tenosynovial giant cell tumor (TGCT), including recurrent disease, Explain the biologic rationale and clinical evidence for the use of targeted options in the management of TGCT, Integrate targeted options into the management of TGCT patients who are unlikely to benefit from surgical interventions, Recommend multidisciplinary approaches for the management of TGCT, including localized and diffuse disease.

Go online to PeerView.com/SUZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView virtual activity, following the 2020 connective tissue oncology annual meeting, a panel of leading clinicians provides insights on important medical evidence supporting targeted agents in tenosynovial giant cell tumor (TGCT), and modern, practical recommendations for overcoming patient care challenges in the management of TGCT. The panel will also provide a multidisciplinary perspective on real-world clinical scenarios and discuss how novel targeted therapeutics have enhanced a long-standing treatment landscape. Upon completion of this activity, participants should be better able to: Describe the clinical signs and symptoms of localized and diffuse tenosynovial giant cell tumor (TGCT), including recurrent disease, Explain the biologic rationale and clinical evidence for the use of targeted options in the management of TGCT, Integrate targeted options into the management of TGCT patients who are unlikely to benefit from surgical interventions, Recommend multidisciplinary approaches for the management of TGCT, including localized and diffuse disease.

Go online to PeerView.com/SUZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView virtual activity, following the 2020 connective tissue oncology annual meeting, a panel of leading clinicians provides insights on important medical evidence supporting targeted agents in tenosynovial giant cell tumor (TGCT), and modern, practical recommendations for overcoming patient care challenges in the management of TGCT. The panel will also provide a multidisciplinary perspective on real-world clinical scenarios and discuss how novel targeted therapeutics have enhanced a long-standing treatment landscape. Upon completion of this activity, participants should be better able to: Describe the clinical signs and symptoms of localized and diffuse tenosynovial giant cell tumor (TGCT), including recurrent disease, Explain the biologic rationale and clinical evidence for the use of targeted options in the management of TGCT, Integrate targeted options into the management of TGCT patients who are unlikely to benefit from surgical interventions, Recommend multidisciplinary approaches for the management of TGCT, including localized and diffuse disease.

Go online to PeerView.com/SUZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView virtual activity, following the 2020 connective tissue oncology annual meeting, a panel of leading clinicians provides insights on important medical evidence supporting targeted agents in tenosynovial giant cell tumor (TGCT), and modern, practical recommendations for overcoming patient care challenges in the management of TGCT. The panel will also provide a multidisciplinary perspective on real-world clinical scenarios and discuss how novel targeted therapeutics have enhanced a long-standing treatment landscape. Upon completion of this activity, participants should be better able to: Describe the clinical signs and symptoms of localized and diffuse tenosynovial giant cell tumor (TGCT), including recurrent disease, Explain the biologic rationale and clinical evidence for the use of targeted options in the management of TGCT, Integrate targeted options into the management of TGCT patients who are unlikely to benefit from surgical interventions, Recommend multidisciplinary approaches for the management of TGCT, including localized and diffuse disease.

Go online to PeerView.com/SUZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView virtual activity, following the 2020 connective tissue oncology annual meeting, a panel of leading clinicians provides insights on important medical evidence supporting targeted agents in tenosynovial giant cell tumor (TGCT), and modern, practical recommendations for overcoming patient care challenges in the management of TGCT. The panel will also provide a multidisciplinary perspective on real-world clinical scenarios and discuss how novel targeted therapeutics have enhanced a long-standing treatment landscape. Upon completion of this activity, participants should be better able to: Describe the clinical signs and symptoms of localized and diffuse tenosynovial giant cell tumor (TGCT), including recurrent disease, Explain the biologic rationale and clinical evidence for the use of targeted options in the management of TGCT, Integrate targeted options into the management of TGCT patients who are unlikely to benefit from surgical interventions, Recommend multidisciplinary approaches for the management of TGCT, including localized and diffuse disease.

Go online to PeerView.com/SUZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView virtual activity, following the 2020 connective tissue oncology annual meeting, a panel of leading clinicians provides insights on important medical evidence supporting targeted agents in tenosynovial giant cell tumor (TGCT), and modern, practical recommendations for overcoming patient care challenges in the management of TGCT. The panel will also provide a multidisciplinary perspective on real-world clinical scenarios and discuss how novel targeted therapeutics have enhanced a long-standing treatment landscape. Upon completion of this activity, participants should be better able to: Describe the clinical signs and symptoms of localized and diffuse tenosynovial giant cell tumor (TGCT), including recurrent disease, Explain the biologic rationale and clinical evidence for the use of targeted options in the management of TGCT, Integrate targeted options into the management of TGCT patients who are unlikely to benefit from surgical interventions, Recommend multidisciplinary approaches for the management of TGCT, including localized and diffuse disease.

In part one of this two-part podcast, William D. Tap, MD, of Memorial Sloan Kettering Cancer Center, discusses new advances in treating patients with sarcoma. 

In part two of this two-part podcast, William D. Tap, MD, of Memorial Sloan Kettering Cancer Center, continues his discussion of new advances in treating patients with sarcoma.